Moberg Pharma announces successful results for MOB-015 in a

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Sep 17, 2014 at 2:15 AM

Moberg Pharma announces successful results for MOB-015 in a Phase II study for the treatment of onychomycosis

Moberg Pharma AB (OMX: MOB) announces successful top-line results from a phase II study for MOB-015 in onychomycosis (nail fungus). The primary endpoint, mycological cure after 15 months, was achieved in 54% of the patients. The purpose of the study was to demonstrate proof-of-concept for MOB-015 in onychomycosis. The open-label clinical study including 25 patients was conducted at Sahlgrenska University Hospital, Sweden with Professor Jan Faergemann as the coordinating investigator. Patients with onychomycosis affecting 25-75% of at least one great toe nail received treatment with MOB-015 during 12 months and were followed for a total of 15 months. The study included patients with more severe onychomycosis than recently published studies of topical treatment alternatives. Of the 24 patients who completed the study, 13 (54%) met the primary endpoint, mycological cure, defined as both negative microscopy and fungal culture after 15 months from start of treatment. The secondary endpoint, mycological cure and excellent clinical improvement or cure was observed in 7 of 24 patients (29%). Biopsies confirmed high levels of terbinafine in the nail plate and nail bed (median values 1610 and 45 ug/g, respectively). MOB015 was generally well tolerated. “The mycological cure rate and clinical outcome in the study are remarkable for a topical treatment. Especially since the majority of these patients had more than 50% nail involvement at inclusion. These results are promising for future phase III studies. An efficacious and safe topical terbinafine product would be highly attractive for Dermatologists worldwide“, stated Dr Jan Faergemann, M.D., Ph.D., Professor, Dermatology Unit at Sahlgrenska University Hospital. "The excellent phase II results exceeded our expectations. MOB-015 has the potential to become a superior and leading product in the large and growing onychomycosis market. We are now proceeding with partner discussions for further development and commercialization of MOB-015”, said Peter Wolpert, CEO of Moberg Pharma AB. About MOB-015 and Onychomycosis MOB-015 is a proprietary topical formulation of terbinafine developed by Moberg Pharma. Terbinafine is currently the most widely used oral prescription treatment for onychomycosis and was a blockbuster before patent expiry. Topical administration of terbinafine eliminates concerns of oral treatment, such as drug interactions or liver injury, but has previously not been successful due to insufficient delivery of the active substance through the nail. Preclinical and clinical data confirm that MOB-015 delivers effective levels of terbinafine through the nail and into the nail bed. Onychomycosis is a common nail infection caused predominantly by dermatophyte fungi that typically occurs under the toenail, though fingernails may also be affected. Approximately 10% of the general population suffers from onychomycosis. The estimated market potential exceeds USD 1 billion in the U.S. only. The untapped potential is significant since the majority of patients are untreated. About this information Moberg Pharma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08.00 am (CET) on September 17th, 2014. For additional information contact: Peter Wolpert, CEO Telephone: +46 (0)70 - 735 71 35 E-mail: peter.wolpert@mobergpharma.se Peter Östling, IR Telephone: +46 (0)76 – 314 09 78 E-mail: peter.ostling@mobergpharma.se About Moberg Pharma Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with a direct sales and marketing organization in the U.S. and an extensive distributor network in more than 40 countries. The company’s OTC portfolio includes the brands Kerasal®, Jointflex®, Kerasal Nail®, Domeboro®, Vanquish®, and Fergon®. Kerasal Nail®(Nalox™ in certain ex-U.S. markets) is the leading product for the treatment of nail disorders in the U.S. and Nordic market. The current portfolio will be supplemented by the acquisition and in-licensing of additional products as well as product development with a focus on innovative drug delivery of proven compounds. Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares (OMX: MOB) are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergpharma.com.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Millrose Faces Class Action: Blame Game in Motion

Millrose Properties: A Realty Ruckus Unfolding Sometimes, in the world of stocks, it feels like you're two steps ahead of the scam or already knee-deep in trouble. Millrose Properties, Inc. struck a rather sour chord recently with an 8.53% stock drop, leaving investors feeling the burn. Here's the juice: a securities fraud class action is in motion, and if you're holding...

St. Croix Financial Hub: Game Changer or Fluff?

You know, sometimes it feels like the financial world gets more tangled than a fishing line on a windy beach. This latest spiel coming out of St. Croix with all its big names and lofty promises—Governor Bryan’s 3rd Wall Street Financial District Hub Initiative—seems like one of those, but maybe it’s got more meat than hype. Half the pitch sounds like your typical...

Cesar Alvarez Honored with Prestigious Miami Award

Cesar Alvarez's Legacy Honored in Miami The Greater Miami Chamber of Commerce's 2026 Sand in My Shoes® Award has found its latest recipient in Cesar L. Alvarez, the Senior Chairman of Greenberg Traurig, P.A. It wasn't just a ceremony—this was a gathering of more than 800 of Miami's business and community power players on October 15, 2026. And man, did it shine a bright...

CTG Data Breach Sparks Class Action Investigation

CTG Faces Scrutiny Over Recent Data Breach Ah, the thrills and spills of the digital age—yet another company stumbling headfirst into a data breach mess. This time, it’s Computer Task Group (CTG) taking center stage, with its IT systems compromised and personal info slipping through the cracks. On September 26, 2026, an unwelcome guest rooted around their network,...

Lazard's Q3 2026: Surging Revenue, Waning Net Income

Breaking Down the Numbers Lazard just dropped its Q3 2026 earnings report, and you can smell both optimism and caution in the air. Sure, $814 million in net revenue isn’t anything to sneeze at, especially when it’s a neat 9% jump from last year’s $748 million. Adjusted figures were a whisker away at $805 million. But dig deeper, and things get a tad less rosy—net...

Mario Lopez: Homegrown Star Hosts Birthday Tequila Bash

Not every day do you get a celeb hitting their home turf just to throwback with fans, but that's Mario Lopez for you. Coming right into San Diego for his birthday month, Lopez isn't just sipping tequila—he’s signing it. Swing by Old Town Tequila and Keg N Bottle this October 24 if you want a bottle of Casa México Tequila adorned with a little star power. Sips,...

New Blood Joins Board: A Power Move for Bank of America

A Fresh Breeze in the Boardroom Bank of America isn't sitting still. They're shaking things up by bringing in Jim Fitterling and Bill Thomas. Now, why’s that a big deal for those watching NYSE:BAC? Well, these guys pack heavy resumes, and their experience could steer the ship with precision across turbulent financial waters. The Minds Behind the Names Let's chew the fat...

Side Bolsters Art Division with Roboto Acquisition

Breaking Into China's Game Art Market The gaming industry's latest buzz centers around Side's acquisition of Roboto Entertainment, a boutique art studio known for crafting immersive game environments. This isn't just another headline grab—this move puts Side smack dab in the heart of China's burgeoning game market with a fresh Chengdu base. Expansion With Strategic...

McLean Guide: Turning Culture Data into Real Action

Unlocking the Potential of Culture Measurement In the corporate jungle, culture is like oxygen. You don’t see it, but you sure as heck feel it when it’s missing or toxic. McLean & Company just dropped a new guide that promises to map out the invisible by measuring organizational culture. Now, you might say, 'Cultural alignment sounds like consultant mumbo-jumbo.' But...

Genedata's AI Push: A Biotech Game-Changer?

A Glimpse into Genedata's Bold AI Integration So, here's a heck of an ambitious move in the biotech sphere with Genedata dropping the news about their integration of NVIDIA's BioNeMo AI models into their R&D workflows. These folks at Genedata are really riding the tech wave, offering up the new RFD4-Proteina release in what they call 'binder design' for biologics...